Fidanacogene elaparvovec Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Fidanacogene elaparvovec Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Phase 3
Highest phase
6
Registered trials
8
Result records
2
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Fidanacogene elaparvovec can convert its AAV based gene therapy profile and factor IX biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Fidanacogene elaparvovec (query alias: Fidanacogene elaparvovec) |
|---|---|
| Modality / target | AAV based gene therapy; factor IX; factor IX modulators |
| Highest global status | Phase 3 |
| Originator | The Children's Hospital of Philadelphia |
| Active developers | Pfizer Inc. |
The MCP disease footprint includes Hemophilia A. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT03861273 | Phase 3 | Active, not recruiting | 51 | Annualized Bleeding Rate (ABR) for Total Bleeds (Treated and Untreated) From Week 12 to Month 15 |
| NCT03307980 | Phase 2 | Active, not recruiting | 21 | Incidence of PF-06838435 related adverse events |
| NCT02484092 | Phase 2 | Completed | 15 | Number of Participants With Clinically Significant Change From Baseline in Physical Examination Findings |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Fidanacogene Elaparvovec for Hemophilia B — A Multiyear Follow-up Study
Phase 1/2; n=15; evaluation: Positive. Reported fields: Adverse Event: factor IX inhibitors = No factor IX inhibitors were detected
Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B
Phase 3; n=45; evaluation: Superior. Reported fields: ABR = 4.42 Unit (95%CI, 1.80 - 7.05); ABR = 1.28 Unit (95%CI, 0.57 - 1.98)
Phase 3, Open-label, Single-arm Study to Evaluate Efficacy and Safety of FIX Gene Transfer With PF-06838435 (rAAV-Spark100-hFIX-R338L) in Adult Male Participants With Moderately Severe to Severe Hemophilia B (FIX:C ≤2%) (BeneGene-2)
Phase 3; n=51; evaluation: not stated. Reported fields: Annualized Bleeding Rate (ABR) for Total Bleeds (Treated and Untreated) From Week 12 to Month 15(Mean) = 4.43 Total bleeds per year (95% Confidence Interval, 1.81 - 7.05); Annualized Bleeding Rate (ABR) for Total Bleeds (Treated and Untreated) From Week 12 to Month 15(Mean) = 1.30 Total bleeds per year (95% Confidence Interval, 0.59 - 2.02); Annualized Bleeding Rate (ABR) for Total Bleeds (Treated and Untreated) From Week 12 to Month 15(Mean): Mean Difference (Final Values) = -3.13(95% CI, -5.44 to -0.81), P-Value = 0.0081
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Fidanacogene elaparvovec addresses Hemophilia A. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—AAV based gene therapy—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2025-04-17 | Children's Hospital of Philadelphia and Royal Prince Alfred Hospital to develop gene therapy fidanacogene elaparvovec to treat Hemophilia B | Not disclosed | Financial terms not disclosed |
| 2014-12-08 | Spark Therapeutics Announces Gene Therapy Collaboration in Hemophilia B with Pfizer Inc. | Not disclosed | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Compositions and methods for modulating factor ix function”. The milestone feed surfaced a patent-application signal described as “Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
